Grifols Sees EPS +30% From 2nd Year Of Talecris Buy
07 Junio 2010 - 3:23AM
Noticias Dow Jones
Spanish plasma products maker Grifols SA (GRF.MC) said Monday
its purchase of Talecris Biotherapeutics Holdings Corp. (TLCR) for
$3.4 billion will boost its earnings per share by 30% from the
second year following completion of the transaction.
In a Spanish regulatory filing, Grifols said its annual sales
will rise to $2.8 billion following the purchase, 58% of which will
come from North America and 28% from Europe.
-By Jonathan House, Dow Jones Newswires; +34 91 395 8120;
jonathan.house@dowjones.com
Grifols (PK) (USOTC:GIKLY)
Gráfica de Acción Histórica
De Jun 2024 a Jul 2024
Grifols (PK) (USOTC:GIKLY)
Gráfica de Acción Histórica
De Jul 2023 a Jul 2024
Real-Time news about Grifols SA (PK) (OTCMarkets): 0 recent articles
Más de Grifols S.A. (ADS) Artículos de Noticias